Nautilus Biotechnology: Karen Akinsanya
Proteomics firm Nautilus Biotechnology has appointed Karen Akinsanya to its board of directors. Akinsanya is currently president of R&D for therapeutics at Schrödinger. Prior to joining Schrödinger, she held positions of increasing responsibility over more than a decade at Merck Research Laboratories, including as associate director of clinical pharmacology; executive director and therapeutic area lead in discovery preclinical and early development; and associate VP of business development and licensing. She holds a bachelor's degree in biochemistry from Queen Mary University of London and a Ph.D. in endocrine physiology from the Royal Postgraduate Medical School at Imperial College London.
Arima Genomics: Chris Roberts
Arima Genomics has appointed Chris Roberts as senior VP of corporate strategy. Roberts comes to Arima from Veracyte, where he led the commercial marketing, product strategy, strategic reimbursement, and field support organizations. He has also held senior leadership roles with HTG Molecular Diagnostics, Caris Life Sciences, and Ventana Medical Systems. Roberts holds an MBA from Duke University.
Delfi Diagnostics: Liz Homans
Delfi Diagnostics has appointed Liz Homans to its board of directors. Homans is currently CEO of Lyell Immunopharma, which she joined when it was founded in 2018. She later served as the company's president prior to becoming CEO in 2020. Before that she held multiple senior leadership positions at Genentech from 2009 to 2018, including VP of US sales. Homans received an MBA from Columbia University and a B.A. in German and economics from Bates University.
For additional recent items on executive appointments and promotions in omics and molecular diagnostics, please see the People in the News page on our website.